Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) Stock Price Down 4.7% – Should You Sell?

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY)’s stock price was down 4.7% during trading on Thursday . The company traded as low as $6.75 and last traded at $6.7850. Approximately 1,251 shares changed hands during trading, a decline of 61% from the average daily volume of 3,221 shares. The stock had previously closed at $7.12.

Clinuvel Pharmaceuticals Price Performance

The stock’s 50 day moving average is $7.82 and its two-hundred day moving average is $7.77.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.